Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Effect of TLR4 and B7-H1 on Immune Escape of Urothelial Bladder Cancer and its Clinical Significance

  • Wang, Yong-Hua (Department of Urology, The Affiliated Hospital of Qingdao University) ;
  • Cao, Yan-Wei (Department of Urology, The Affiliated Hospital of Qingdao University) ;
  • Yang, Xue-Cheng (Department of Urology, The Affiliated Hospital of Qingdao University) ;
  • Niu, Hai-Tao (Department of Urology, The Affiliated Hospital of Qingdao University) ;
  • Sun, Li-Jiang (Department of Urology, The Affiliated Hospital of Qingdao University) ;
  • Wang, Xin-Sheng (Department of Urology, The Affiliated Hospital of Qingdao University) ;
  • Liu, Jing (Department of Pediatrics, The Affiliated Hospital of Qingdao University)
  • Published : 2014.02.01
Download PDF
⟨ Previous Next ⟩

Abstract

Background/Aim: Toll-like receptor 4 (TLR4) and B7-H1, both normally expressed restricted to immune cells, are found to be aberrantly expressed in a majority of human tumors and may play important roles in regulation of tumor immunity. It has been shown that urothelial bladder cancer (UBC) patients can manifest tumoral immune escape which may be a potential critical factor in tumor pathogenesis and progression. However, so far, the mechanisms of UBC-related immune escape have not been clarified. The aim of this study was to investigate the effect of TLR4 and B7-H1 on immune escape of UBC. Methods: Bladder cancer T24 cells were pre-incubated with LPS and co-cultured with tumor specific CTLs. CTL cytotoxicity and apoptosis rates were measured by MTT assay and flow cytometry, respectively. The effects of an ERK inhibitor on B7-H1 expression and CTL cytotoxicity against T24 cells were also evaluated. In addition, TLR4, B7-H1 and PD-1 protein expression was analyzed by immunohistochemistry in 60 UBC specimens and 10 normal urothelia. Results: TLR4 activation protected T24 cells from CTL killing via B7-H1 overexpression. However PD98059, an inhibitor of ERK, enhanced CTL killing of T24 cells by reducing B7-H1 expression. TLR4 expression was generally decreased in UBC specimens, while B7-H1 and PD-1 were greatly overexpressed. Moreover, expression of both B7-H1 and PD-1 was significantly associated with UICC stage and WHO grade classification. Conclusions: TLR4 and B7-H1 may contribute to immune escape of UBC. Targeting B7-H1 or the ERK pathway may offer new immunotherapy strategies for bladder cancer.

Keywords

References

  1. Ayari C, Bergeron A, LaRue H, et al (2011). Toll-like receptors in normal and malignant human bladders. J Urol, 2011, 185, 1915-21. https://doi.org/10.1016/j.juro.2010.12.097
  2. Babjuk M, Burger M, Zigeuner R, et al (2013). EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013. Eur Urol, 64, 639-53. https://doi.org/10.1016/j.eururo.2013.06.003
  3. Biragyn A, Ruffini PA, Leifer CA, et al (2002). Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science, 298, 1025-9. https://doi.org/10.1126/science.1075565
  4. Blank C, Brown I, Peterson AC, et al (2004). PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res, 64, 1140-5. https://doi.org/10.1158/0008-5472.CAN-03-3259
  5. Dong H, Strome SE, Salomao DR, et al (2002). Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med, 8, 793-800.
  6. Elhag OA, Hu XJ, Wen-Ying Z, et al (2012). Reconstructed adeno-associated virus with the extracellular domain of murine PD-1 induces antitumor immunity. Asian Pac J Cancer Prev, 13, 4031-6. https://doi.org/10.7314/APJCP.2012.13.8.4031
  7. Ghebeh H, Mohammed S, Al-Omair A, et al (2006). The B7-H1 (PD-L1) T lymphocyte- inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia, 8, 190-8. https://doi.org/10.1593/neo.05733
  8. Gong XH, Wang YH, Shao SX, et al (2013). Role of TLR4-signaling pathway in the immune evasion of bladder cancer and its mechanism. Chin J Cancer Prev Treat, 20, 1217-20.
  9. Hasan A, Ghebeh H, Lehe C, et al (2011). Therapeutic targeting of B7-H1 in breast cancer. Expert Opin Ther Targets, 15, 1211-25. https://doi.org/10.1517/14728222.2011.613826
  10. Herr HW, Bean MA, Whitmore WF Jr (1976). Decreased ability of blood leukocytes from patients with tumors of the urinary bladder to act as stimulator cells in mixed leukocyte culture. Cancer Res, 36, 2754-60.
  11. Huang B, Zhao J, Li H, et al (2005). Toll-Like Receptors on Tumor Cells Facilitate Evasion of Immune Surveillance. Cancer Res, 65, 5009-14. https://doi.org/10.1158/0008-5472.CAN-05-0784
  12. Inman BA, Sebo TJ, Frigola X, et al (2007). PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCGinduced granulomata: associations with localized stage progression. Cancer, 109, 1499-505. https://doi.org/10.1002/cncr.22588
  13. Iwai Y, Ishida M, Tanaka Y, et al (2002). Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA, 99, 12293-7. https://doi.org/10.1073/pnas.192461099
  14. Kaufman DS, Shipley WU, Feldman AS (2009). Bladder cancer. Lancet, 374, 239-49. https://doi.org/10.1016/S0140-6736(09)60491-8
  15. Konishi J, Yamazaki K, Azuma M, et al (2004). B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res, 10, 5094-100. https://doi.org/10.1158/1078-0432.CCR-04-0428
  16. Liu J, Hamrouni A, Wolowiec D, et al (2007). Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood, 110, 296-304. https://doi.org/10.1182/blood-2006-10-051482
  17. Loskog A, Ninalga C, Paul-Wetterberg G, et al (2007). Human bladder carcinoma is dominated by T-regulatory cells and Th1 inhibitory cytokines. J Urol, 177, 353-8. https://doi.org/10.1016/j.juro.2006.08.078
  18. Mukamel E, Shohat B, Servadio C (1982). Immunological profile of patients with transitional cell carcinoma of the bladder. Br J Urol, 54, 11-5. https://doi.org/10.1111/j.1464-410X.1982.tb13503.x
  19. Okudaira K, Hokari R, Tsuzuki Y, et al (2009). Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model. Int J Oncol, 35, 741-9.
  20. Patard JJ, Saint F, Velotti F, et al (1998). Immune response following intravesical Bacillus Calmette-Guerin instillations in superficial bladder cancer: a review. Urol Res, 26, 155-9. https://doi.org/10.1007/s002400050039
  21. Qian Y, Deng J, Geng L, et al (2008). TLR4 signaling induces B7-H1 expression through MAPK pathways in bladder cancer cells. Cancer Invest, 26, 816-21. https://doi.org/10.1080/07357900801941852
  22. Song J, Abraham SN (2008). TLR-mediated immune responses in the urinary tract. Curr Opin Microbiol, 11, 66-73. https://doi.org/10.1016/j.mib.2007.12.001
  23. Sun Q, Liu Q, Zheng Y, et a1 (2008). Rapamycin suppresses TLR4-triggered IL-6 and PGE2 production of colon cancer cells by inhibiting TLR4 expression and NF-kappa B activation. Mol lmmunol, 45, 2929-36.
  24. Thompson RH, Kuntz SM, Leibovich BC, et al (2006). Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res, 66, 3381-5. https://doi.org/10.1158/0008-5472.CAN-05-4303
  25. Tsujihashi H, Matsuda H, Uejima S, et al (1989). Immunoresponse of tissue infiltrating lymphocytes in bladder tumors. J Urol, 141, 1467-70.
  26. Vabulas RM, Wagner H, Schild H (2002). Heat shock proteins as ligands of toll-like receptors. Curr Top Microbiol Immunol, 270, 169-84.
  27. Zhang D, Zhang G, Hayden MS, et al (2004). A toll-like receptor that prevents infection by uropathogenic bacteria. Science, 303, 1522-6. https://doi.org/10.1126/science.1094351

Cited by

  1. IL-12 Regulates B7-H1 Expression in Ovarian Cancer-associated Macrophages by Effects on NF-κB Signalling vol.15, pp.14, 2014, https://doi.org/10.7314/APJCP.2014.15.14.5767
  2. VSIG4 expression on macrophages facilitates lung cancer development vol.94, pp.7, 2014, https://doi.org/10.1038/labinvest.2014.73
  3. TLR4 has a TP53-dependent dual role in regulating breast cancer cell growth vol.112, pp.25, 2015, https://doi.org/10.1073/pnas.1420811112
  4. Pattern Recognition Receptors in Cancer Progression and Metastasis vol.8, pp.1179-0644, 2015, https://doi.org/10.4137/CGM.S24314
  5. Urothelial Cancer: Inflammatory Mediators and Implications for Immunotherapy vol.30, pp.4, 2016, https://doi.org/10.1007/s40259-016-0176-3
  6. Dynamics of Immune Checkpoints, Immune System, and BCG in the Treatment of Superficial Bladder Cancer vol.2017, pp.1748-6718, 2017, https://doi.org/10.1155/2017/3573082
  7. T cells responses in oral lichen planus vol.26, pp.5, 2017, https://doi.org/10.1111/exd.13244
  8. Expression of TLR4 in Non-Small Cell Lung Cancer Is Associated with PD-L1 and Poor Prognosis in Patients Receiving Pulmonectomy vol.8, pp.1664-3224, 2017, https://doi.org/10.3389/fimmu.2017.00456
  9. Clinicopathologic Significance and Prognostic Value of B7 Homolog 1 in Gastric Cancer vol.94, pp.43, 2015, https://doi.org/10.1097/MD.0000000000001911
  10. T-cell immunoglobulin mucin-3 expression in bladder urothelial carcinoma: Clinicopathologic correlations and association with survival vol.112, pp.4, 2015, https://doi.org/10.1002/jso.24012
  11. Prognostic Role of PD-L1 in Malignant Solid Tumors: A Meta-Analysis vol.32, pp.1, 2017, https://doi.org/10.5301/jbm.5000225
  12. Clinical Role of Programmed Cell Death-1 Expression in Patients with Non-muscle-invasive Bladder Cancer Recurring After Initial Bacillus Calmette–Guérin Therapy vol.25, pp.8, 2018, https://doi.org/10.1245/s10434-018-6498-2